AU2020334980A1 - Neuromelanin-sensitive MRI for assessing Parkinson's disease - Google Patents

Neuromelanin-sensitive MRI for assessing Parkinson's disease Download PDF

Info

Publication number
AU2020334980A1
AU2020334980A1 AU2020334980A AU2020334980A AU2020334980A1 AU 2020334980 A1 AU2020334980 A1 AU 2020334980A1 AU 2020334980 A AU2020334980 A AU 2020334980A AU 2020334980 A AU2020334980 A AU 2020334980A AU 2020334980 A1 AU2020334980 A1 AU 2020334980A1
Authority
AU
Australia
Prior art keywords
neuromelanin
mri
disease
parkinson
years
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020334980A
Other languages
English (en)
Inventor
Clifford Mills CASSIDY
Samuel CLARK
Guillermo HORGA HERNANDEZ
Kenneth WENGLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Research Foundation for Mental Hygiene Inc
Terran Biosciences Inc
Original Assignee
Columbia University in the City of New York
Research Foundation for Mental Hygiene Inc
Terran Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York, Research Foundation for Mental Hygiene Inc, Terran Biosciences Inc filed Critical Columbia University in the City of New York
Publication of AU2020334980A1 publication Critical patent/AU2020334980A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/70—Means for positioning the patient in relation to the detecting, measuring or recording means
    • A61B5/702—Posture restraints
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5608—Data processing and visualization specially adapted for MR, e.g. for feature analysis and pattern recognition on the basis of measured MR data, segmentation of measured MR data, edge contour detection on the basis of measured MR data, for enhancing measured MR data in terms of signal-to-noise ratio by means of noise filtering or apodization, for enhancing measured MR data in terms of resolution by means for deblurring, windowing, zero filling, or generation of gray-scaled images, colour-coded images or images displaying vectors instead of pixels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Developmental Disabilities (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
AU2020334980A 2019-08-20 2020-08-17 Neuromelanin-sensitive MRI for assessing Parkinson's disease Abandoned AU2020334980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889300P 2019-08-20 2019-08-20
US62/889,300 2019-08-20
PCT/US2020/046686 WO2021034770A1 (en) 2019-08-20 2020-08-17 Neuromelanin-sensitive mri for assessing parkinson's disease

Publications (1)

Publication Number Publication Date
AU2020334980A1 true AU2020334980A1 (en) 2022-03-03

Family

ID=74660631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020334980A Abandoned AU2020334980A1 (en) 2019-08-20 2020-08-17 Neuromelanin-sensitive MRI for assessing Parkinson's disease

Country Status (10)

Country Link
US (2) US20220273184A1 (https=)
EP (1) EP4018202A4 (https=)
JP (2) JP2022545083A (https=)
KR (2) KR20220100851A (https=)
CN (1) CN114787631A (https=)
AU (1) AU2020334980A1 (https=)
CA (1) CA3151632A1 (https=)
IL (1) IL290693A (https=)
MX (1) MX2022002105A (https=)
WO (1) WO2021034770A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10955423B2 (en) 2015-12-15 2021-03-23 The General Hospital Corporation Methods of estimating blood glucose and related systems
US11293852B2 (en) 2016-04-07 2022-04-05 The General Hospital Corporation White blood cell population dynamics
US20220273184A1 (en) * 2019-08-20 2022-09-01 Terran Biosciences, Inc. Neuromelanin-sensitive mri for assessing parkinson's disease
TWI781463B (zh) * 2020-10-15 2022-10-21 臺北醫學大學 腦部多巴胺轉運體檢查系統及其運作方法
JP2024510080A (ja) * 2021-03-11 2024-03-06 テラン バイオサイエンシズ インコーポレイテッド バイオマーカーを含む撮像データセットのハーモナイゼーションのためのシステム、デバイス及び方法
EP4312729A4 (en) * 2021-04-02 2025-02-26 Spintech, Inc. SYSTEMS AND METHODS FOR TEMPLATE-BASED AUTOMATIC RECOGNITION OF ANATOMICAL STRUCTURES
WO2022266654A1 (en) * 2021-06-16 2022-12-22 The General Hospital Corporation Methods to characterize functional and dysfunctional acute inflammatory responses to pathologic processes
US11911170B2 (en) * 2021-09-13 2024-02-27 Christopher J. Rourk Deep brain sensing and stimulation probe
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
WO2023235766A2 (en) * 2022-05-31 2023-12-07 University Of Ottawa Institute Of Mental Health Research Methods for acquiring and analyzing neuromelanin-sensitive mri
US12599313B2 (en) * 2022-06-23 2026-04-14 ViBo Health LLC Health trackers for autonomous targeting of tissue sampling sites
CN114999657A (zh) * 2022-08-03 2022-09-02 首都医科大学附属北京友谊医院 评估帕金森病患者的神经纤维束与步态障碍的相关性的方法和相关产品
US20260049105A1 (en) * 2022-08-18 2026-02-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss
WO2024081800A1 (en) * 2022-10-12 2024-04-18 Octave Bioscience, Inc. Measuring brain volumes for modeling neurological disease state
CN115735857B (zh) * 2022-11-24 2025-11-18 江苏珂玛麒生物科技有限公司 一种帕金森病动物模型的构建方法
KR102906269B1 (ko) * 2023-08-03 2026-01-02 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법
CN116740064B (zh) * 2023-08-14 2023-10-20 山东奥洛瑞医疗科技有限公司 一种核磁共振肿瘤区域提取方法
CN117372437B (zh) * 2023-12-08 2024-02-23 安徽农业大学 用于面神经麻痹智能化检测与量化方法及其系统
KR102832391B1 (ko) * 2024-08-13 2025-07-14 주식회사 휴런 Mri영상에서 뉴로멜라닌의 탈침착 정량화를 위한 이미지 처리방법 및 그 처리장치
KR102834035B1 (ko) * 2024-08-16 2025-07-21 주식회사 휴런 3d 멀티 에코 gre를 이용한 뉴로멜라닌과 나이그로좀1의 동시 촬영 및 이미지 처리방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288545B1 (en) * 1999-03-22 2001-09-11 General Electric Company Method and apparatus for calibration of RF and gradient field time delays
EP1332363A4 (en) * 2000-10-09 2007-08-29 Kay Double PROOF OF NEURODEGENERATIVE DISEASES
US20070275944A1 (en) * 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
EP2844143B1 (en) * 2012-05-04 2023-07-19 Emory University Method for imaging and determining information associated with regions of the brain
US9600778B2 (en) * 2013-07-02 2017-03-21 Surgical Information Sciences, Inc. Method for a brain region location and shape prediction
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
ES2822201T3 (es) * 2014-06-12 2021-04-29 Commissariat Energie Atomique Método de IRM para cuantificar la cantidad de hierro en tejidos utilizando difusión por imágenes de resonancia magnética
WO2016154682A1 (en) * 2015-04-02 2016-10-06 Crc For Mental Health Ltd Method for predicting risk of cognitive deterioration
US11352671B2 (en) * 2015-05-01 2022-06-07 Vanderbilt University Predicting therapeutic response in Parkinson's disease
WO2017053718A2 (en) * 2015-09-23 2017-03-30 Boston Medical Center Corporation Biomarkers for the early detection of parkinson's disease
EP3547252B1 (en) * 2016-12-28 2025-10-22 Shanghai United Imaging Healthcare Co., Ltd. Multi-modal image processing system and method
CN113271985A (zh) * 2018-08-07 2021-08-17 悦智有限公司 用于诊断多巴胺能和运动障碍的方法
US20220273184A1 (en) * 2019-08-20 2022-09-01 Terran Biosciences, Inc. Neuromelanin-sensitive mri for assessing parkinson's disease

Also Published As

Publication number Publication date
EP4018202A1 (en) 2022-06-29
KR20250110932A (ko) 2025-07-21
CA3151632A1 (en) 2021-02-25
WO2021034770A1 (en) 2021-02-25
EP4018202A4 (en) 2023-11-01
CN114787631A (zh) 2022-07-22
JP2025074118A (ja) 2025-05-13
KR20220100851A (ko) 2022-07-18
JP2022545083A (ja) 2022-10-25
MX2022002105A (es) 2022-08-04
IL290693A (en) 2022-04-01
US20220273184A1 (en) 2022-09-01
US20260007323A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
US20260007323A1 (en) Neuromelanin-sensitive mri for assessing parkinson's disease
Bangen et al. Cognitive dispersion is a sensitive marker for early neurodegenerative changes and functional decline in nondemented older adults.
Pauls et al. Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition
US20020058867A1 (en) Method and apparatus for measuring indices of brain activity during motivational and emotional function
US20230389854A1 (en) Neuromelanin-sensitive mri and methods of use thereof
US20190083805A1 (en) Detecting or treating post-traumatic stress syndrome
US20230200716A1 (en) Use of neuromelanin-sensitive mri as a biomarker of dopamine function
Whiteside et al. The effect of behavior therapy on caudate N-acetyl-l-aspartic acid in adults with obsessive–compulsive disorder
US10534052B2 (en) FMRI biomarker of neurodegenerative disease
McCormick et al. Antipsychotic effect of electroconvulsive therapy is related to normalization of subgenual cingulate theta activity in psychotic depression
Mark et al. MRI infarction load and CI therapy outcomes for chronic post-stroke hemiparesis
Long et al. Brain structural changes underlying clinical symptom improvement following fast-acting treatments in treatment resistant depression
CN116745858A (zh) 神经黑色素敏感性mri及其使用方法
Mieling Functional and structural changes in the progression of Alzheimer's disease: insights from human imaging
Shirzadi Application of Cerebral Hemodynamic Imaging in Neurodegenerative Diseases
Orban Amygdala resting state functional connectivity in alcohol dependence
Beaver et al. INSPIRES-in-patient support program in recovery from stroke-“the voice (s) of experience”
Horga et al. Striatal dopamine s nthesis capacit and neuromelanin in the substantia nigra: a multimodal imaging stud in schizophrenia and health controls

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period